Search Results
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease
More news about: RedHill Biopharma Ltd.
Dec 01, 2025, 07:00 ET RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine
More news about: RedHill Biopharma Ltd.
Nov 20, 2025, 06:00 ET Small Modular Reactor Market to Reach USD 6.48 Billion by 2031 as Global Energy Systems Shift Toward Safe, Modular & Low-Carbon Power | According to DataM Intelligence
2. ARC Clean Energy (U.S./Canada) Delivering a sodium-cooled fast reactor inspired by EBR-II technology. Strong traction in Canada with plans for industrial heat applications. 3. Holtec International
More news about: DataM Intelligence 4 Market Research LLP
Nov 12, 2025, 02:29 ET EQT agrees to sale of shares in Azelis Group NV
affiliate of the funds called EQT VIII ("EQT") is pleased to announce it has signed a definitive agreement to sell c. 44 million shares in Azelis Group NV (EBR: AZE) (the "Company") to JNE Partners, First Pacific Advisors, LP's managed funds and accounts, and Temasek, all existing shareholders of the Company,
More news about: EQT
Nov 07, 2025, 08:00 ET EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients
https://www.ebrsystemsinc.com/. About EBR Systems EBR Systems is a cardiac rhythm management company on a clear mission: to transform the lives of people with heart failure by
More news about: EBR Systems
Nov 04, 2025, 12:01 ET RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at
More news about: RedHill Biopharma Ltd.
Oct 28, 2025, 06:00 ET InstantGMP Launches Fully Integrated Laboratory Information Management System (LIMS) software
of outdated testing methods. Unlike conventional LIMS solutions that require complex and costly integration with ERP, MES, or EBR systems, InstantGMP's LIMS is purpose-built for GMP manufacturers and GLP laboratories. Delivered as part of the InstantGMP PRO SaaS platform, it brings
More news about: InstantGMP, Inc.
Oct 23, 2025, 11:09 ET Built In Launches Recruitment Industry's First Platform to Help Companies Measure and Shape Employer Reputation to Convert Talent in an AI-First Hiring Market
both candidates and AI. One of the platform's most powerful features, the Employer Brand Reputation (EBR) Score, is now available to every company. The EBR Score and accompanying report analyze how AI models describe each company across seven key employer brand pillars: workplace
More news about: Built In
Oct 22, 2025, 16:50 ET RedHill Biopharma Receives Nasdaq Staff Determination Notification
3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at
More news about: RedHill Biopharma
Oct 20, 2025, 09:05 ET CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at
More news about: Cumberland Pharmaceuticals Inc.
Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at
More news about: RedHill Biopharma Ltd.
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
3 study for acute gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available at
More news about: RedHill Biopharma Ltd.
Sep 29, 2025, 07:00 ET RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
gastroenteritis and gastritis and positive results from a U.S. Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America. More information about the Company is available
More news about: RedHill Biopharma Ltd.